Adjunctive treatment of behavioral disorders in patients with cognitive deficit.

Q3 Pharmacology, Toxicology and Pharmaceutics
Ivana Tašková
{"title":"Adjunctive treatment of behavioral disorders in patients with cognitive deficit.","authors":"Ivana Tašková","doi":"10.36290/csf.2024.043","DOIUrl":null,"url":null,"abstract":"<p><p>Adjunctive treatment of behavioral disorders in patients with cognitive deficit The article provides an overview of the pharmacotherapy of behavioural and psychological symptoms of dementia (BPSD) in the context of evidence-based medicine. Its goal is to provide readers with a practical and educational overview of managing these symptoms. Cognitive disorders, including dementia, result from the disruption of higher cortical functions of the brain. Dementia often manifests not only through cognitive dysfunction but also through BPSD, such as agitation, aggression, anxiety, psychosis, and sleep disturbances. These symptoms affect up to 97% of patients with dementia and significantly reduce the quality of life for both patients and caregivers. BPSD are often more stressful for patients and caregivers than the cognitive symptoms themselves. Behavioural symptoms include a wide range of manifestations from non-aggressive forms such as pacing and repetitive movements to aggressive and agitated behaviour (verbal and physical). Psychological symptoms can include depression, anxiety, and psychotic symptoms such as paranoia and delusions. The causes of BPSD can be varied, as well as their risk factors (including e.g. co-medication, comorbidities, the patient's personality traits, inappropriate communication by caregivers, and environmental influences). The pharmacotherapy of BPSD is complex and often involves the use of antipsychotics, antidepressants, benzodiazepines, or acetylcholinesterase inhibitors and memantine. Due to the diversity of manifestations and causes of BPSD, a unified pharmacotherapeutic approach cannot be applied. Non-pharmacological approaches should always be preferred, except in cases of severe depression, psychosis, or aggression that may endanger the patient or someone else. In practice, many medications indicated for BPSD therapy are used off-label. The pharmacotherapy of BPSD should only begin after ruling out other causes of BPSD. Furthermore, it should only be initiated after considering all risks and potential benefits, starting with low geriatric doses, monitoring side effects, regularly reassessing effectiveness, and administering medications for the shortest possible duration should be also applied.</p>","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"73 4","pages":"245-250"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ceska a Slovenska Farmacie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36290/csf.2024.043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Adjunctive treatment of behavioral disorders in patients with cognitive deficit The article provides an overview of the pharmacotherapy of behavioural and psychological symptoms of dementia (BPSD) in the context of evidence-based medicine. Its goal is to provide readers with a practical and educational overview of managing these symptoms. Cognitive disorders, including dementia, result from the disruption of higher cortical functions of the brain. Dementia often manifests not only through cognitive dysfunction but also through BPSD, such as agitation, aggression, anxiety, psychosis, and sleep disturbances. These symptoms affect up to 97% of patients with dementia and significantly reduce the quality of life for both patients and caregivers. BPSD are often more stressful for patients and caregivers than the cognitive symptoms themselves. Behavioural symptoms include a wide range of manifestations from non-aggressive forms such as pacing and repetitive movements to aggressive and agitated behaviour (verbal and physical). Psychological symptoms can include depression, anxiety, and psychotic symptoms such as paranoia and delusions. The causes of BPSD can be varied, as well as their risk factors (including e.g. co-medication, comorbidities, the patient's personality traits, inappropriate communication by caregivers, and environmental influences). The pharmacotherapy of BPSD is complex and often involves the use of antipsychotics, antidepressants, benzodiazepines, or acetylcholinesterase inhibitors and memantine. Due to the diversity of manifestations and causes of BPSD, a unified pharmacotherapeutic approach cannot be applied. Non-pharmacological approaches should always be preferred, except in cases of severe depression, psychosis, or aggression that may endanger the patient or someone else. In practice, many medications indicated for BPSD therapy are used off-label. The pharmacotherapy of BPSD should only begin after ruling out other causes of BPSD. Furthermore, it should only be initiated after considering all risks and potential benefits, starting with low geriatric doses, monitoring side effects, regularly reassessing effectiveness, and administering medications for the shortest possible duration should be also applied.

认知缺陷患者行为障碍的辅助治疗。
认知缺陷患者行为障碍的辅助治疗本文概述了在循证医学背景下对痴呆(BPSD)行为和心理症状的药物治疗。其目标是为读者提供管理这些症状的实用和教育概述。认知障碍,包括痴呆症,是由大脑高级皮层功能的破坏引起的。痴呆症不仅表现为认知功能障碍,还表现为BPSD,如躁动、攻击、焦虑、精神病和睡眠障碍。这些症状影响多达97%的痴呆症患者,并显著降低患者和护理人员的生活质量。对于患者和护理人员来说,BPSD通常比认知症状本身更有压力。行为症状包括范围广泛的表现,从踱步和重复运动等非攻击性形式到攻击性和激动行为(言语和身体)。心理症状包括抑郁、焦虑和精神病症状,如偏执和妄想。BPSD的病因可能多种多样,其风险因素也可能多种多样(例如,共同用药、合并症、患者的个性特征、护理人员的不当沟通以及环境影响)。BPSD的药物治疗很复杂,通常涉及抗精神病药、抗抑郁药、苯二氮卓类药物或乙酰胆碱酯酶抑制剂和美金刚的使用。由于BPSD的表现和病因的多样性,不能采用统一的药物治疗方法。除了严重的抑郁症、精神病或可能危及患者或他人的攻击行为外,非药物治疗方法应始终是首选。在实践中,许多用于BPSD治疗的药物是在标签外使用的。BPSD的药物治疗应该在排除其他原因后才开始。此外,只有在考虑了所有风险和潜在益处之后,才应该开始使用,从低老年剂量开始,监测副作用,定期重新评估有效性,并在尽可能短的时间内给药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Ceska a Slovenska Farmacie
Ceska a Slovenska Farmacie Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
0.90
自引率
0.00%
发文量
22
期刊介绍: Přehledový článek je zaměřen zejména na metody přípravy, charakterizaci mikročástic a dále na charakteristiku a příklady jejich možného využití ve farmakoterapii. Mikročástice jako...
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信